Quality of Life and Relapse of Duodenal Ulcer Before and After Eradication of Helicobacter Pylori

Overview

Journal Scand J Gastroenterol

Publisher Informa Healthcare

Specialty Gastroenterology

Date 1994 Oct 1

PMID 7839092

Citations 8

Authors

I Wilhelmsen

A Berstad

Affiliations

Soon will be listed here.

Abstract

Background: The aim of the study was to compare relapse rates and quality of life before and after eradication of Helicobacter pylori in a group of patients with documented recurrent duodenal ulcer disease.

Methods: Seventy-four patients with three endoscopically verified duodenal ulcers during the past 2 years received triple treatment consisting of bismuth subnitrate, oxytetracycline, and metronidazole for 14 days. Quality of life was measured with the Psychosocial Adjustment to Illness Scale (PAIS-SR) and H. pylori status with the 14C-urea breath test.

Results: After triple treatment H. pylori was eradicated in 96%, and the ulcer was healed in all. Ulcer relapse was reduced from 100% before to 1.4% during a mean observation time of 111 weeks. The H. pylori reinfection rate was 2.4% during the 1st year. The patients were more satisfied with the health care system and had better sexual relationship and less psychologic distress 1 year after eradication of H. pylori than before.

Conclusions: For patients with recurrent duodenal ulcer, eradication of H. pylori with triple treatment leads to a significantly reduced ulcer relapse rate and improved quality of life.

Citing Articles

Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil.

Suzuki R, Lopes R, da Camara Lopes G, Hung Ho T, Speranca M BMC Gastroenterol. 2013; 13:164.

PMID: 24305035 PMC: 4235177. DOI: 10.1186/1471-230X-13-164.

16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori.

Gerrits M, de Zoete M, Arents N, Kuipers E, Kusters J Antimicrob Agents Chemother. 2002; 46(9):2996-3000.

PMID: 12183259 PMC: 127406. DOI: 10.1128/AAC.46.9.2996-3000.2002.

Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in Western Sydney between 1990 and 1998.

Xia H, Phung N, Altiparmak E, Berry A, Matheson M, Talley N Dig Dis Sci. 2002; 46(12):2716-23.

PMID: 11768265 DOI: 10.1023/a:1012731614075.

Six-year follow-up after Helicobacter pylori eradication in peptic ulcer disease.

OConnor H, Stewart C, Walsh R, McGee C, Flynn B Ir J Med Sci. 2001; 170(1):24-7.

PMID: 11440407 DOI: 10.1007/BF03167715.

Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.

Tavakoli M, Prach A, Malek M, Hopwood D, Senior B, Murray F Pharmacoeconomics. 2000; 16(4):355-65.

PMID: 10623364 DOI: 10.2165/00019053-199916040-00004.